Windtree Therapeutics (WINT) vs. Soligenix (SNGX) Head-To-Head Survey

Windtree Therapeutics (OTCMKTS: WINT) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Windtree Therapeutics and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
Soligenix -90.93% -112.81% -71.98%

Insider & Institutional Ownership

0.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Soligenix shares are owned by institutional investors. 0.8% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Windtree Therapeutics and Soligenix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 25.16 -$39.49 million ($71.83) -0.01
Soligenix $10.45 million 1.81 -$3.24 million ($1.04) -2.09

Soligenix has higher revenue and earnings than Windtree Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Windtree Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Windtree Therapeutics and Soligenix, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
Soligenix 0 0 2 0 3.00

Soligenix has a consensus target price of $5.25, suggesting a potential upside of 141.94%. Given Soligenix’s stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Windtree Therapeutics.

Summary

Soligenix beats Windtree Therapeutics on 11 of the 14 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply